SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
Saved in:
| Title: | SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. |
|---|---|
| Authors: | Johansson P; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. patricia.johansson@uk-essen.de.; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany. patricia.johansson@uk-essen.de., Klein-Hitpass L; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Choidas A; Lead Discovery Center GmbH, Dortmund, Germany., Habenberger P; Lead Discovery Center GmbH, Dortmund, Germany., Mahboubi B; Center for Drug Discovery, Department of Pediatrics, Emory Center for AIDS Research, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA., Kim B; Center for Drug Discovery, Department of Pediatrics, Emory Center for AIDS Research, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA., Bergmann A; Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig Holstein, Kiel, Germany., Scholtysik R; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Brauser M; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Lollies A; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Siebert R; Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig Holstein, Kiel, Germany.; Institute of Human Genetics, University of Ulm and University Hospital of Ulm, Ulm, Germany., Zenz T; Department of Molecular Therapy in Haematology and Oncology, National Center for Tumor Diseases and German Cancer Research Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Dührsen U; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Küppers R; Institute of Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Dürig J; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany. |
| Source: | Blood cancer journal [Blood Cancer J] 2018 Jan 19; Vol. 8 (1), pp. 11. Date of Electronic Publication: 2018 Jan 19. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-017-0036-5 |
